Zanubrutinib for Waldenstrom’s Macroglobulinemia (WM)
European Hematology Association (EHA) congress 2020
Professor Judith Trotman
Director of the Haematology Clinical Research Unit
Concord Hospital, Sydney
Professor Judith Trotman spoke to Donna Gairns, National Nurse Director from Lymphoma Australia about the outcomes of trials in patients with Waldenstrom's macroglobulinemia. This was presented during the EHA conference held 11-21 June 2020.
Professor Trotman discussed the results from the early Phase study of Zanubrutinb in comparison to the first-generation BTK inhibitor ibrutinib in patients with Waldenstrom’s macroglobulinemia. Professor Trotman also highlighted how the longer-term follow-up data from this study complements the promising response rates and side-effect profile shown in the ASPEN study.
Professor Trotman discussed her experience with using zanubrutinib and the good results experienced by patients.
For a full list of abstracts that were discussed, visit the Lymphoma Australia website:
www.lymphoma.org.au/news/140/...
For support, contact the Lymphoma Nurse Support Line - 1800 953 081 or email enquiries@lymphoma.org.au
21 июн 2020
